| P50 | author | Michael P. Whyte | Q89919619 |
| | Steven Mumm | Q95336496 |
| | William H. McAlister | Q117472672 |
| P2093 | author name string | Michael T Collins | |
| | Mark S Anderson | |
| | Edward C Hsiao | |
| | Ivan El-Sayed | |
| | Andrew E Horvai | |
| | Dolores M Shoback | |
| | Anne L Schafer | |
| | Andrea M Tom | |
| | Frederick V Schaefer | |
| P2860 | cites work | RANK is essential for osteoclast and lymph node development | Q24598872 |
| | Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 |
| | Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis | Q28141482 |
| | OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 |
| | Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression | Q33944735 |
| | Familial expansile osteolysis (excessive RANK effect) in a 5-generation American kindred | Q34559155 |
| | Activating mutations of the stimulatory G protein in the McCune-Albright syndrome | Q34981177 |
| | Signal peptide mutations in RANK prevent downstream activation of NF-κB. | Q36043987 |
| | Cancer to bone: a fatal attraction | Q36884628 |
| | RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism | Q37108966 |
| | Targeting RANK/RANKL in the treatment of solid tumours and myeloma | Q37694726 |
| | New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis. | Q37748586 |
| | Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease. | Q43039149 |
| | Clinical and biochemical response of TNFRSF11A-mediated early-onset familial Paget disease to bisphosphonate therapy | Q46330772 |
| | Osteoprotegerin deficiency and juvenile Paget's disease | Q48292818 |
| | Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. | Q50335960 |
| | Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene. | Q50482693 |
| | The diagnostic utility of the GNAS mutation in patients with fibrous dysplasia: meta-analysis of 168 sporadic cases. | Q54329444 |
| | Mutation Screening of the TNFRSF11A Gene Encoding Receptor Activator of NFkB (RANK) in Familial and Sporadic Paget's Disease of Bone and Osteosarcoma | Q57534153 |
| | Giant cell tumor of bone: a unique paradigm of stromal-hematopoietic cellular interactions | Q72809734 |
| | Effect of alendronate treatment on the clinical picture and bone turnover markers in chronic idiopathic hyperphosphatasia | Q73535394 |
| | Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis | Q77435071 |
| | RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone | Q77684008 |
| | Osteogenic sarcoma in a child with familial expansile osteolysis syndrome: an accidental association? | Q82959449 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bone disease | Q4941552 |
| P304 | page(s) | 911-921 | |
| P577 | publication date | 2014-04-01 | |
| P1433 | published in | Journal of Bone and Mineral Research | Q15750941 |
| P1476 | title | Panostotic expansile bone disease with massive jaw tumor formation and a novel mutation in the signal peptide of RANK. | |
| P478 | volume | 29 | |